Vaccines

Potential impact of future TB vaccines in high HIV prevalent settings and aging populations

Aims: Estimate the epidemiological impact of potential TB vaccines in high burden settings with high HIV prevalence; Estimate the epidemiological impact of potential TB vaccines in high burden settings with ageing populations; Model outcomes can be used to prioritise development of vaccine candidates with greatest potential public health impact

People: Rebecca Harris, Tom Sumner, Gwen Knight (Imperial), Richard White, and colleagues

Funding: Medical Research Council


Modelling to accelerate TB vaccine candidate selection

Aims: Develop a framework in which mathematical models are used to better understand human and animal immune response to TB vaccination using available immunological data from the IC31 adjuvanted protein vaccine; Predict the best dose of the vaccine in terms of immunogenicity in humans based on varying dose-response data in animals

People: Sophie Rhodes, Tom Evans (Aeras), Steven Kern (BMGF), Gwen Knight (Imperial), Richard White, Helen Fletcher

Funding: Aeras


 

 

Closed projects

Potential global cost-effectiveness of future TB vaccines

Aims: To evaluate the potential cost-effectiveness of future tuberculosis vaccines

People: Gwen Knight, Richard White, Ulla Griffiths, Anna Vassall

Funding: Aeras

Comments are closed.